Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer.

about

Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer

P2860

Q58751440-163C41BF-CEC8-4E9D-8FCE-049FB3CC4498

P2860

Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer.

Item

http://www.wikidata.org/entity/Q47110241

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Biomarkers/Molecular Targets, ...... or Non-Small Cell Lung Cancer.

@en

Biomarkers/Molecular Targets, ...... or Non-Small Cell Lung Cancer.

@nl

type

Item

label

Biomarkers/Molecular Targets, ...... or Non-Small Cell Lung Cancer.

@en

Biomarkers/Molecular Targets, ...... or Non-Small Cell Lung Cancer.

@nl

prefLabel

Biomarkers/Molecular Targets, ...... or Non-Small Cell Lung Cancer.

@en

Biomarkers/Molecular Targets, ...... or Non-Small Cell Lung Cancer.

@nl

P1476

Biomarkers/Molecular Targets, ...... for Non-Small Cell Lung Cancer

@en

P2093

Elizabeth S Waxman

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

ROS1 rearrangements define a unique molecular class of lung cancers.

P304

514-524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JADPRO.2016.7.5.4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Frank V Fossella

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29282427

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5737399

http://www.w3.org/2001/XMLSchema#string

Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer.

about

P2860

P2860

Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932